Veena Somayaji - Concepedia

Author

Veena Somayaji

Pfizer (United States)

Also Known As

Somayaji, Veena, V. Somayaji, Veena R. Somayaji, Veena Somayaji

Publications

1.5K

Citations

H-Index

Concepts

All Affiliations

Pfizer (United States)

About

Veena Somayaji is an author at Pfizer (United States) specializing in medicine, pharmacology, and health sciences.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	817
2	Health Sciences	5	5	792
3	Diabetes	3	3	709
4	Allergy	2	2	89
5	Cell Biology	1	1	477

Veena Somayaji

Publications

1.4K

Citations

H-Index

Page 1

	Year	Citations
A Long-Acting FGF21 Molecule, PF-05231023, Decreases Body Weight and Improves Lipid Profile in Non-human Primates and Type 2 Diabetic Subjects Saswata Talukdar, Yingjiang Zhou, Dongmei Li, Cell Metabolism ObesityMetabolic SyndromeLong-acting Fgf21 MoleculeGrowth HormoneMetabolic Disorder	2016	477
ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials Roberto A. Calle, Neeta B. Amin, Santos Carvajal‐Gonzalez, Nature Medicine ObesityMetabolic SyndromeDgat2 InhibitorHepatologyAcc Inhibitor	2021	207
Once‐weekly administration of a long‐acting fibroblast growth factor 21 analogue modulates lipids, bone turnover markers, blood pressure and body weight differently in obese people with hypertriglyceridaemia and in non‐human primates Albert M. Kim, Veena Somayaji, Jennifer Dong, Diabetes Obesity and Metabolism	2017	136
Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene Michael R. McClung, Ethel S. Siris, Steve Cummings, Menopause The Journal of The North American Menopause Society	2006	109
Pharmacokinetics and pharmacodynamics of PF‐05231023, a novel long‐acting FGF21 mimetic, in a first‐in‐human study Jennifer Dong, Michelle I. Rossulek, Veena Somayaji, British Journal of Clinical Pharmacology	2015	98
Pharmacologic inhibition of ketohexokinase prevents fructose-induced metabolic dysfunction Jemy A. Gutierrez, Wei Liu, Sylvie Perez, Molecular Metabolism	2021	80
Inhibition of ketohexokinase in adults with NAFLD reduces liver fat and inflammatory markers: A randomized phase 2 trial David J. Kazierad, Kristin Chidsey, Veena Somayaji, Med Fatty Liver DiseaseRandomized Phase 2ObesityMetabolic SyndromeInflammation	2021	72
Meta-Analysis of Clinical Dose–Response in a Large Drug Development Portfolio Neal Thomas, Kevin Sweeney, Veena Somayaji Statistics in Biopharmaceutical Research	2014	65
Effects of multiple ascending doses of the glucagon receptor antagonist <scp>PF</scp> ‐06291874 in patients with type 2 diabetes mellitus David J. Kazierad, Arthur Bergman, Beijing Tan, Diabetes Obesity and Metabolism	2016	45
Efficacy and safety of the glucagon receptor antagonist PF‐06291874: A 12‐week, randomized, dose‐response study in patients with type 2 diabetes mellitus on background metformin therapy David J. Kazierad, Kristin Chidsey, Veena Somayaji, Diabetes Obesity and Metabolism	2018	29

Page 1